ArticleFrontiers in neurology2025
Comparing burden of ischemic stroke caused by high low-density lipoprotein cholesterol in global and China: trends and projections.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic stroke (IS) remains a major global cause of death and disability, with elevated low-density lipoprotein cholesterol (LDL-C) identified as a key modifiable risk factor. This study evaluates the global and Chinese burden of IS attributable to high LDL-C from 1990 to 2021, and projects future trends through 2046. Materials and methods: Data on IS mortality, disability-adjusted life years (DALYs), and age-standardized rates (ASRs) were sourced from the Global Burden of Disease (GBD) 2021 database. Analyses were stratified by age and sex. Temporal trends were assessed using Joinpoint regression, calculating the annual percentage change (APC) and the average annual percentage change (AAPC). Future burden was projected using the Nordpred model. Results: In 2021, IS deaths due to high LDL-C reached 936,192 globally (an increase of 43.04%) and 300,053 in China (an increase of 161.86%), despite age-standardized mortality rate (ASMR) declining by 43.16% and 12.61%, respectively. DALYs increased by 44.55% globally and 126.94% in China, with smaller reductions in age-standardized DALY rate (ASDR). Mortality and DALYs increased with age and were higher in men. China's elderly (≥90 years) exhibited particularly high mortality (1,058.69/100,000) compared to the global ≥95 age group (482.32/100,000). AAPCs indicated more consistent declines globally than in China. Projections estimate IS deaths will reach 1.86 million globally and 630,000 in China by 2046, with DALYs rising to 36.8 million and 11.4 million, respectively. China's projected ASMR and ASDR will remain higher than global averages. Conclusion: Despite declines in age-standardized rates, the absolute burden of IS attributable to high LDL-C continues to rise globally, driven by population aging and growth. China, in particular, faces a disproportionately higher burden compared to global trends, with slower progress in reducing these rates. Significant age- and sex-based disparities remain. These findings underscore the urgent need for targeted public health strategies to address the growing burden of IS, particularly in China, by focusing on effective LDL-C management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.